Vaccine Therapies in Malignant Glioma

[1]  Tyler E. Miller,et al.  Brain tumor stem cells: Molecular characteristics and their impact on therapy. , 2014, Molecular aspects of medicine.

[2]  Gelareh Zadeh,et al.  GBM's multifaceted landscape: highlighting regional and microenvironmental heterogeneity. , 2014, Neuro-oncology.

[3]  A. Parsa,et al.  Vaccine therapies for patients with glioblastoma , 2014, Journal of Neuro-Oncology.

[4]  M. Ivan,et al.  PI3K pathway inhibitors: potential prospects as adjuncts to vaccine immunotherapy for glioblastoma. , 2014, Immunotherapy.

[5]  Z. Berneman,et al.  Clinical use of dendritic cells for cancer therapy. , 2014, The Lancet. Oncology.

[6]  L. Liau,et al.  Cytokine responsiveness of CD8+ T cells is a reproducible biomarker for the clinical efficacy of dendritic cell vaccination in glioblastoma patients , 2014, Journal of Immunotherapy for Cancer.

[7]  L. Delamarre,et al.  Dendritic Cell-Targeted Vaccines , 2014, Front. Immunol..

[8]  C. Qiu,et al.  CTL responses to HSP47 associated with the prolonged survival of patients with glioblastomas , 2014, Neurology.

[9]  M. Weller,et al.  Immunological challenges for peptide-based immunotherapy in glioblastoma. , 2014, Cancer treatment reviews.

[10]  Susan M. Chang,et al.  Heat-shock protein peptide complex-96 vaccination for recurrent glioblastoma: a phase II, single-arm trial. , 2014, Neuro-oncology.

[11]  Christopher M. Jackson,et al.  Vaccine strategies for glioblastoma: progress and future directions. , 2013, Immunotherapy.

[12]  T. Cloughesy,et al.  Comparison of Glioma-associated Antigen Peptide-loaded Versus Autologous Tumor Lysate-loaded Dendritic Cell Vaccination in Malignant Glioma Patients , 2013, Journal of immunotherapy.

[13]  H. Rammensee,et al.  Natural HLA class I ligands from glioblastoma: extending the options for immunotherapy , 2013, Journal of Neuro-Oncology.

[14]  T. Decker,et al.  The regulation of inflammation by interferons and their STATs , 2013, JAK-STAT.

[15]  E. Chiocca,et al.  The Spectrum of Vaccine Therapies for Patients With Glioblastoma Multiforme , 2012, Current Treatment Options in Oncology.

[16]  Susan M. Chang,et al.  Individual Patient-Specific Immunity against High-Grade Glioma after Vaccination with Autologous Tumor Derived Peptides Bound to the 96 KD Chaperone Protein , 2012, Clinical Cancer Research.

[17]  S. Phuphanich,et al.  Phase I trial of a multi-epitope-pulsed dendritic cell vaccine for patients with newly diagnosed glioblastoma , 2012, Cancer Immunology, Immunotherapy.

[18]  P. Wen,et al.  Current clinical development of PI3K pathway inhibitors in glioblastoma. , 2012, Neuro-oncology.

[19]  L. Liau,et al.  Monitoring of Regulatory T Cell Frequencies and Expression of CTLA-4 on T Cells, before and after DC Vaccination, Can Predict Survival in GBM Patients , 2012, PloS one.

[20]  Gordon Li,et al.  Targeting EGF receptor variant III: tumor-specific peptide vaccination for malignant gliomas , 2012, Expert review of vaccines.

[21]  L. Boon,et al.  Immunotherapy with PI3K inhibitor and Toll-like receptor agonist induces IFN-γ+IL-17+ polyfunctional T cells that mediate rejection of murine tumors. , 2012, Cancer research.

[22]  Christopher M. Jackson,et al.  Challenges in Immunotherapy Presented by the Glioblastoma Multiforme Microenvironment , 2011, Clinical & developmental immunology.

[23]  R. Binder,et al.  CD91-dependent programming of T-helper cell responses following heat shock protein immunization. , 2011, Nature communications.

[24]  Jian-xin Lin,et al.  IL-2 family cytokines: new insights into the complex roles of IL-2 as a broad regulator of T helper cell differentiation. , 2011, Current opinion in immunology.

[25]  C. Brancolini,et al.  Type I IFNs signaling and apoptosis resistance in glioblastoma cells , 2011, Apoptosis.

[26]  I. Yang,et al.  Heat shock protein–peptide complex in the treatment of glioblastoma , 2011, Expert review of vaccines.

[27]  J. Engh,et al.  Induction of CD8+ T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with {alpha}-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in patients with recurrent malignant glioma. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  S. Nelson,et al.  Gene Expression Profile Correlates with T-Cell Infiltration and Relative Survival in Glioblastoma Patients Vaccinated with Dendritic Cell Immunotherapy , 2010, Clinical Cancer Research.

[29]  Raymond Sawaya,et al.  Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  Jeffrey A Jones,et al.  Phosphatidylinositol 3-kinase- inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals , 2010 .

[31]  Richard A. Flavell,et al.  The polarization of immune cells in the tumour environment by TGFβ , 2010, Nature Reviews Immunology.

[32]  S. Gabriel,et al.  Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. , 2010, Cancer cell.

[33]  A. Friedman,et al.  An epidermal growth factor receptor variant III–targeted vaccine is safe and immunogenic in patients with glioblastoma multiforme , 2009, Molecular Cancer Therapeutics.

[34]  K. Shokat,et al.  T cell receptor signaling controls Foxp3 expression via PI3K, Akt, and mTOR , 2008, Proceedings of the National Academy of Sciences.

[35]  R. Sciot,et al.  Postoperative Adjuvant Dendritic Cell–Based Immunotherapy in Patients with Relapsed Glioblastoma Multiforme , 2008, Clinical Cancer Research.

[36]  R. Yamanaka,et al.  Cell- and peptide-based immunotherapeutic approaches for glioma. , 2008, Trends in molecular medicine.

[37]  Makiya Nishikawa,et al.  Heat shock protein derivatives for delivery of antigens to antigen presenting cells. , 2008, International journal of pharmaceutics.

[38]  Peter Fecci,et al.  Molecular strategies for the treatment of malignant glioma—genes, viruses, and vaccines , 2008, Neurosurgical Review.

[39]  D. Sakas,et al.  Comparative analysis of peripheral and localised cytokine secretion in glioblastoma patients. , 2007, Cytokine.

[40]  D. Crooks,et al.  Th1/Th2 cytokine imbalance in meningioma, anaplastic astrocytoma and glioblastoma multiforme patients. , 2006, Oncology reports.

[41]  A. Dalmasso,et al.  IL-4 and IL-13 Induce Protection of Porcine Endothelial Cells from Killing by Human Complement and from Apoptosis through Activation of a Phosphatidylinositide 3-Kinase/Akt Pathway1 , 2005, The Journal of Immunology.

[42]  Timothy F. Cloughesy,et al.  Dendritic Cell Vaccination in Glioblastoma Patients Induces Systemic and Intracranial T-cell Responses Modulated by the Local Central Nervous System Tumor Microenvironment , 2005, Clinical Cancer Research.

[43]  Martin J. van den Bent,et al.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.

[44]  D. Kufe,et al.  Vaccination of Glioma Patients with Fusions of Dendritic and Glioma Cells and Recombinant Human Interleukin 12 , 2004, Journal of immunotherapy.

[45]  A. Friedman,et al.  Epidermal growth factor receptor VIII peptide vaccination is efficacious against established intracerebral tumors. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[46]  Haidong Dong,et al.  Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion , 2002, Nature Medicine.

[47]  Michael Rehli,et al.  Novel Signal Transduction Pathway Utilized by Extracellular HSP70 , 2002, The Journal of Biological Chemistry.

[48]  D. Bigner,et al.  EGF mutant receptor vIII as a molecular target in cancer therapy. , 2001, Endocrine-related cancer.

[49]  P. Srivastava,et al.  CD91 is a common receptor for heat shock proteins gp96, hsp90, hsp70, and calreticulin. , 2001, Immunity.

[50]  A. Belldegrun,et al.  Treatment of a glioblastoma patient by vaccination with autologous dendritic cells pulsed with allogeneic major histocompatibility complex class I-matched tumor peptides , 2000 .

[51]  P. Srivastava,et al.  Necrotic but not apoptotic cell death releases heat shock proteins, which deliver a partial maturation signal to dendritic cells and activate the NF-kappa B pathway. , 2000, International immunology.

[52]  H. Rammensee,et al.  Cross-Presentation of Glycoprotein 96–Associated Antigens on Major Histocompatibility Complex Class I Molecules Requires Receptor-Mediated Endocytosis , 2000, The Journal of experimental medicine.

[53]  Stuart K. Calderwood,et al.  HSP70 stimulates cytokine production through a CD14-dependant pathway, demonstrating its dual role as a chaperone and cytokine , 2000, Nature Medicine.

[54]  F. Hartl,et al.  Roles of molecular chaperones in cytoplasmic protein folding. , 2000, Seminars in cell & developmental biology.

[55]  P. Srivastava,et al.  A mechanism for the specific immunogenicity of heat shock protein-chaperoned peptides. , 1995, Science.

[56]  P. Humphrey,et al.  Structural alterations of the epidermal growth factor receptor gene in human gliomas. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[57]  P. Humphrey,et al.  Anti-synthetic peptide antibody reacting at the fusion junction of deletion-mutant epidermal growth factor receptors in human glioblastoma. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[58]  P. Humphrey,et al.  Amplification and expression of the epidermal growth factor receptor gene in human glioma xenografts. , 1988, Cancer research.

[59]  D. Louis,et al.  Diagnostic and therapeutic avenues for glioblastoma: no longer a dead end? , 2013, Nature Reviews Clinical Oncology.

[60]  A. Heimberger,et al.  The role of tregs in glioma-mediated immunosuppression: potential target for intervention. , 2010, Neurosurgery clinics of North America.

[61]  P. Mischel,et al.  Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma , 2007, Nature Medicine.